|
Jul 16
|
High Growth Tech Stocks In Asia For July 2025
|
|
Jul 8
|
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
|
|
Jun 15
|
Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients
|
|
Mar 12
|
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
|
|
Mar 9
|
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
|
|
Feb 24
|
EC authorises Celltrion’s Avtozma for multiple indications
|
|
Feb 11
|
/C O R R E C T I O N -- Celltrion/
|
|
Aug 26
|
Celltrion’s SteQeyma receives EC approval for chronic inflammatory diseases
|
|
Jan 11
|
Celltrion presents strategic vision and growth plan at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Jul 5
|
Celltrion launches biosimilar of AbbVie's blockbuster drug Humira in US
|